文献速递治疗药物监测与药物基因组学特殊人群用药

CYP2C19与CYP2B6胚系变异对环磷酰胺药代动力学及临床结局的重要性

The importance of both CYP2C19 and CYP2B6 germline variations in cyclophosphamide pharmacokinetics and clinical outcomes.
PubMed 文献 · Br J Clin Pharmacol · 2019-07-22

本文是一篇聚焦性综述,汇总13项药代动力学研究和17项治疗结局研究,涵盖血液恶性肿瘤、乳腺癌、系统性红斑狼疮及清髓移植等情形。证据提示CYP2C19和CYP2B6的胚系药物遗传学变异均影响环磷酰胺的生物活化,ALDH1A1变异亦有报道。未来需综合评估这3个药物基因并分析基因-基因交互,以确认发现并支持个体化方案。

要点

  • 环磷酰胺为前药,需生物活化生成活性磷酰胺芥才能发挥疗效。
  • CYP2C19与CYP2B6胚系变异均与环磷酰胺生物活化相关。
  • ALDH1A1变异对环磷酰胺药代动力学或结局的作用亦有报道。

核心结论

  • CYP2C19和CYP2B6的胚系药物遗传学变异均影响环磷酰胺的生物活化,证据来自药代动力学与治疗结局研究。
  • ALDH1A1药物遗传学变异对环磷酰胺的作用亦有报道。
  • 未来需综合评估CYP2C19、CYP2B6和ALDH1A1并分析基因-基因交互,以确认发现并可能实现个体化治疗。

研究设计与样本

  • 聚焦性综述,汇总13项药代动力学研究和17项治疗结局研究。
  • 研究情境涵盖血液恶性肿瘤、乳腺癌、系统性红斑狼疮和清髓移植。

主要发现

  • 13项药代动力学研究和17项治疗结局研究提示CYP2C19与CYP2B6变异影响环磷酰胺生物活化。
  • ALDH1A1药物遗传学变异的作用亦有报道。

临床怎么用

  • 临床可关注CYP2C19、CYP2B6及ALDH1A1变异对环磷酰胺活化与结局的潜在影响。
  • 未来在确认基因-基因交互后,或可据此制定个体化环磷酰胺治疗方案。

局限性

  • 综述指出需综合评估3个药物基因并分析基因-基因交互,以确认现有发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cyclophosphamide is an alkylating agent used in the treatment of solid and haematological malignancies and as an immunosuppressive agent. As a prodrug, it is dependent on bioactivation to the active phosphoramide mustard metabolite to elicit its therapeutic effect. This focused review will highlight the evidence for the role of germline pharmacogenetic variation in both plasma pharmacokinetics and clinical outcomes. There is a substantial indication from 13 pharmacokinetic and 17 therapeutic outcome studies, in contexts as diverse as haematological malignancy, breast cancer, systemic lupus erythematosus and myeloablation, that pharmacogenetic variation in both CYP2C19 and CYP2B6 influence the bioactivation of cyclophosphamide. An additional role for pharmacogenetic variation in ALDH1A1 has also been reported. Future studies should comprehensively assess these 3 pharmacogenes and undertake appropriate statistical analysis of gene-gene interactions to confirm these findings and may allow personalised treatment regimens.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Helsby NA, Yong M, van Kan M, et al. The importance of both CYP2C19 and CYP2B6 germline variations in cyclophosphamide pharmacokinetics and clinical outcomes. Br J Clin Pharmacol. 2019. PMID: 31218720. doi:10.1111/bcp.14031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。